Web Results

www.ildcollaborative.org/resources/phase-iii-ipf-clinical-trials

PRM-151 is an experimental medication being developed and tested by Promedior, Inc. PRM-151 is a protein called human pentraxin-2 that is grown and purified ...

pharmastore.informa.com/product/idiopathic-pulmonary-fibrosis-ipf

The majority of pipeline drugs in development are administered via the oral route. High-impact upcoming events in the IPF space comprise topline Phase IIa trial ...

www.purdue.edu/newsroom/releases/2020/Q4/targeted-therapies-developed-to-reduce-lung-fibrosis.html

Nov 11, 2020 ... ... Professor of Chemistry and Presidential Scholar for Drug Discovery, has led a team to develop two targeted therapies for people with IPF.

jtd.amegroups.com/article/view/28653/html

Nintedanib and pirfenidone were approved by the FDA for the treatment of IPF in 2014 based on positive phase 3 trials, and both of these antifibrotic drugs are ...

www.frontiersin.org/articles/10.3389/fphar.2018.00499/full

May 17, 2018 ... ... pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis ( IPF) has fueled interest in the development of additional drugs ...

www.biospace.com/article/biogen-halts-mid-stage-ipf-drug-trial-due-to-safety-concerns

Sep 17, 2019 ... The other drug approved by the FDA for IPF is Genentech's Esbriet. That drug, first developed by Brisbane, Calif.-based InterMune, was ...

www.businesswire.com/news/home/20191104005337/en/Global-Idiopathic-Pulmonary-Fibrosis-IPF-Market-Spotlight-2019-2027-Roches-Esbriet-and-Boehringer-Ingelheims-Ofev-are-the-only-approved-drugs-for-IPF---ResearchAndMarkets.com

Nov 4, 2019 ... Industry-sponsored drugs in active clinical development for IPF are spread evenly across Phase I and Phase II, with two drugs in Phase III.

www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-expands-idiopathic-pulmonary-fibrosis-ipf-pipeline-through

Boehringer Ingelheim has developed OFEV ® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and ...

ipf-summit.com

Overcome Translational & Clinical Challenges to Develop More Effective & Disease-Modifying IPF Drugs. Accelerate the Development of More Meaningful &  ...

www.openaccessjournals.com/articles/clinical-trials-of-idiopathic-pulmonary-fibrosis-choosing-the-right-primary-end-point.pdf

Drug development in IPF has proven challenging with exceedingly high clinical trial failure rates. With the goal of delivering safe and effective therapies to our ...